Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose
NCT04278898
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 3 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Stanford University
- Last updated on ClinicalTrials.gov
- May 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford University School of Medicine · Stanford, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.